Category Archives: Genetics

Animal Genetics Cable Market Analysis with Market Size, Industry Share, trends and Forecast to 2025 – Scientect

Animal Genetics CableMarket Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast and Business Opportunity.

Download Premium Sample of the Report:https://brandessenceresearch.biz/Request/Sample?ResearchPostId=137&RequestType=Sample

Global Animal Genetics Cable Market Size Study by End-Use Industry (Building & Construction, Automotive & Transportation, Manufacturing, Energy) By Insulation Material (XPLE, LSZH, PVC, EPR) and Regional Forecasts 2017-2025.Global Animal Genetics Cable Market to reach USD 8.7 billion by 2025.

Global Animal Genetics Cable Market valued approximately USD 3.62 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.30% over the forecast period 2017-2025. The driving force for the growth of the Animal Genetics Cable Market is that this market is mainly driven by increasing animal protein consumption, rising adoption of advanced genetic technologies for larger-scale production and quality breeds, as well as development for cutting-edge technologies in animal genetic testing.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

oBy TypeAnimal Genetic ProductsoLive AnimalsoPoultryoPorcineoBovineoCanineoGenetic MaterialsoSemenoBovineoPorcineoCanineoEquineoEmbryooBovineoEquineoAnimal Testing ServicesoDNA TypingoGenetic Trait TestsoGenetic Disease TestsBy Regions:oNorth AmericaoU.S.oCanadaoEuropeoUKoGermanyoAsia PacificoChinaoIndiaoJapanoRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2015Base year 2016Forecast period 2017 to 2025

Some of the key manufacturers involved in the market are Genus Plc (U.K.), Topigs (Netherlands), Envigo (U.S.), CRV Holding B.V. (Netherlands), Hendrix Genetics BV (Netherlands), Groupe Grimaud (France), Neogen Corporation (U.S.), Alta Genetics (Canada), VetGen (U.S.), Zoetis, Inc. (U.S.), and Animal Genetics, Inc. (U.S.). Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the Global Animal Genetics Cable in Market Study:

oKey Consulting Companies & AdvisorsoLarge, medium-sized, and small enterprisesoVenture capitalistsoValue-Added Resellers (VARs)oThird-party knowledge providersoInvestment bankersoInvestors

Key factors influencing market growth:

Request Customization of the Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=137&RequestType=Methodology

Customization of the Report:

Brandessence Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Animal Genetics Cable market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/blood-bank-information-system-market-size-2020-to-show-impressive-growth-by-2025-industry-trends-share-top-key-players-analysis-and-forecast-research-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/us-orthopedics-medical-imaging-market-size-research-study-including-growth-factors-market-dynamics-and-forecast-to-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/vascular-access-device-market-size-2020-share-demand-types-top-key-players-and-forecast-to-2025-2020-08-12?tesla=y

https://www.pharmiweb.com/press-release/2020-08-12/nuclear-medicine-market-size-2020-growing-demand-analysis-industry-growth-regional-revenue-top

https://www.pharmiweb.com/press-release/2020-08-12/dengue-testing-market-size-2020-global-share-industry-analysis-technology-trends-top-leaders-gr

View original post here:
Animal Genetics Cable Market Analysis with Market Size, Industry Share, trends and Forecast to 2025 - Scientect

Genetic Counseling Market to Witness an Outstanding Growth During 2020 | AT-GC, Ancestry, Arup Laboratories, Biron Health Group, Color Genomics,…

The Global Genetic Counseling Market provides up-to-date information on current and future industry trends, enabling readers to identify products and services to increase revenue growth and profitability. This research report provides in-depth study of all key factors affecting global and regional markets, including drivers, imprisonment, threats, challenges, opportunities and industry-specific trends. This report cites worldwide trust and specimens with leading players downstream and upstream analysis.

Request Sample Copy of this [emailprotected]: https://www.theresearchinsights.com/request_sample.php?id=255631

This market research report on analyzes the growth prospects for the key vendors operating in this market space including AT-GC, Ancestry, Arup Laboratories, Biron Health Group, Color Genomics, EasyDNA, GenPath Diagnostics (an Opko Health Company), GeneDX (an Opko Health Company), GeneHealth UK, GeneMatters, GeneScreen, Genome Medical, InformedDNA, Invitae Corporation, Laboratory Corporation of America, Metis Genetics, MyOncoPath, Quest Diagnostics Incorporated, Veritas Genetics

Technological advancements in the Genetic Counseling Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period. In addition to the complete assessment of the market, the report presents Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry validated market data.

Asia Pacific is the most advanced market for Genetic Counseling. This growth is largely driven by factors such as population perspective improvement and increased awareness. In addition, Latin Americas value-based healthcare services market will expand to a significant CAGR. Brazil and Mexico are leading the value-based health care services market in the region because of the favorable businesses that governments are promoting. Moreover, as research and development develops, market growth in Latin America will accelerate.

Get Reasonable Discount on this Premium Report @: https://www.theresearchinsights.com/ask_for_discount.php?id=255631

Key questions answered in the report include:

This report provides an effective business outlook, different case studies from various top-level industry experts, business owners, and policymakers have been included to get a clear vision about business methodologies to the readers. SWOT and Porters Five model have been used for analyzing the Global Genetic Counseling Market on the basis of strengths, challenges and Global opportunities in front of the businesses.

Enquiry Before [emailprotected] https://www.theresearchinsights.com/enquiry_before_buying.php?id=255631

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About us:

The Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us:

Robin

Sales manager

Contact number: +91-996-067-0000

[emailprotected]

https://www.theresearchinsights.com

Here is the original post:
Genetic Counseling Market to Witness an Outstanding Growth During 2020 | AT-GC, Ancestry, Arup Laboratories, Biron Health Group, Color Genomics,...

NIH scientists credited with breakthrough in treating a genetic disorder – Federal News Network

Best listening experience is on Chrome, Firefox or Safari. Subscribe to Federal Drives daily audio interviews onApple PodcastsorPodcastOne.

A major breakthrough in treating a genetic disorder can be credited to our next guest. Sickle cell disease is a blood disorder that affects more than 20 million people worldwide. Theyve recently had a breakthrough. Federal News Networks Eric White spoke to one of the scientists at the National Institutes of Health conducting research on sickle cell on Federal Drive with Tom Temin. Dr. John Tisdale is a finalist in this years Service to America Medals program.

Dr. John Tisdale: I trained in internal medicine, and that was in the early 90s. I encountered patients with sickle cell disease who were experiencing extraordinary pain. And at that time, all we had was pain medication. So we would give pain medication and IV fluids because very often dehydration was what provoked the pain episode in these patients. But we had no specific treatments, nothing that were directed at the disease itself, only management of the pain. It was strange to me because I had learned about sickle cell disease in genetics classes and had known that we knew the basis for this disease longer than any other disease, yet we had no treatment, nothing. So it motivated me to think about ways that could treat the disease. The obvious thing that came to mind was a bone marrow transplant because we had a very active bone marrow transplant service at Vanderbilt. And I found that a very exciting way to approach disease and it just made sense that if you have a blood disease that causes all this difficulty in blood comes from the bone marrow well one obvious way to fix it is just to replace the bone marrow with one that doesnt have the genetics that causes the disease, like a brother or sister that we were doing for other kinds of diseases, and that could potentially cure the disease. And in fact, I learned that it had been done before in a patient who had leukemia. And that was a reason for her getting a bone marrow transplant. But she also had sickle cell disease and she was cured of both. There were some efforts during that time to bring that to the clinic, in the pediatric setting, and everything is always easier with kids because theyre tougher when it comes to medications and transplants and all the things that you can think of doing, chemotherapy. That got me motivated into studying hematology and bone marrow transplant, and trying to figure out ways to bring bone marrow transplant to patients with sickle cell disease.

Eric White: This sickle cell disease, obviously weve all heard of it. Even if you know what it is, its still a complicated disease. Can you explain what is the latest research says that sickle cell disease actually does over? As I said its a very strange disease that affects the body in many different ways. Are there any new findings as to how it does actually affect it?

Dr. John Tisdale: Well, I think weve known for a very long time exactly what happens in this disease. It arose as a way to protect from death from malaria. So just one little letter off for the gene that makes our hemoglobin, and hemoglobin is the molecule in red blood cells that carries oxygen around the blood. So one letter off in part of that molecule, and you have protection from malaria, you dont get the very severe form of malaria because the red cell is not as hospitable to the parasite. So that gets selected for in areas where theres malaria, like in Sub Saharan Africa. But if you get two copies of the gene, one from mom and one from dad, you get this disease, sickle cell disease because the hemoglobin now is different than the normal hemoglobin. Instead of carrying oxygen around and staying in solution like it does normally, you have a hemoglobin that once it does its job by dropping off oxygen out in the body, it can come out of solution and become like rock hard, distort the shape of the red cell thats normally squeezing through blood vessels to find its way back to the lungs to get more oxygen. When that happens, block the circulation. So it kind of causes a log jam and all the blood behind it gets stuck. And so wherever that happens, gets starved of its oxygen. So I mean, if it happens in the brain, for example, it causes a stroke. And so kids, eight years old can have a stroke that looks exactly like the sort that we see in the elderly who have vascular disease. If it happens in the muscle, its extremely painful or in the bone. And it happens in every organ in the body. And as a result can damage those organs over time and significantly shorten the lifespan of patients with sickle cell disease. So the lifespan currently is in the 40s. And thats much improved over the last several decades, but its still much lower than then people without the disease.

Eric White: So with your research, what has given you the most promise? What results have you all hung on to whether its bone marrow transplant or gene therapy? Is there one that you say hey, we might be on to something here?

Dr. John Tisdale: Well, I think the biggest breakthrough that weve made is figuring out just how much of the bone marrow we have to fix. So it turns out, we dont have to completely replace the bone marrow with somebody elses bone marrow to make the blood normal. So normally in a bone marrow transplant you you have to give chemotherapy to take away all of the cells that are making blood. Thats kind of like tilling the garden, right? You cant go out in the middle of a cornfield and spread a bunch of tomato seeds and expect to have tomatoes there, theyre not going to grow because the corns already growing. So the thinking is to do a bone marrow transplant, you have to harvest the corn, till the soil, plant the sees. And the same is true for bone marrow transplants. But it turns out for sickle cell disease, we dont have to do that. Weve had patients who even though we try to get rid of all their bone marrow, we failed and they had up to 80% of their own bone marrow still making blood, and presumably sickle blood. But if we had only 20% from the donor that was making normal blood, that would result in all of the blood being normal. And thats just because sickle cells live 10 or 12 days in the circulation, normal cells live 120 days in the circulation. And since the normal cells have such an advantage, you dont really have to completely eradicate the patients own bone marrow or you dont have to fix every cell. So thats important. That told us two things. One, we dont have to use toxic chemotherapy that we normally have to use to do a bone marrow transplant. And furthermore, we can start to think about gene therapy as an approach because we know we can never fix every cell. But if we could fix 20% of cells, we would predict from what weve observed in patients getting transplants from their brother or sister, that wed be able to fix the disease. And were well above the 20% mark when we transfer genes into cells. We can also correct the mutation at higher than 20%. So knowing that we only have to get to 20% has allowed us to start clinical trials, using the patients own bone marrow where we take those seeds out and try to fix them and give them back. If we can make 20%, we think we can fix the disease.

Eric White: Is there anything else that youd like to get the word out on? Is there any way people might be able to help or if if they have any family members who are suffering from this, if theres anything you would like to tell them?

Dr. John Tisdale: Well, I mean, I think the thing thats very important to understand for anyone with a genetic disease or otherwise is that clinical trials are the way that we make progress. And so participating in clinical trials is important for moving the field forward, and we partner with our patients and their family and their support structure to do these clinical trials and to make progress in the disease. So its extraordinarily important for people to understand that. Thats the way we make progress.

Continued here:
NIH scientists credited with breakthrough in treating a genetic disorder - Federal News Network

Increased Access to Germline Testing Needed in Prostate Cancer – OncLive

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.1

Results from the retrospective study done in a total of 986 patients with prostate cancer who participated in a sponsored testing program showed that 16% (n = 153) of patients who underwent genetic testing had positive germline result; of these patients, 14% (n = 138) had pathogenic (P)/likely pathogenic (LP) variants and 1.5% (n = 15) had increased risk alleles (IRAs). Moreover, these patients were found to have 167 P/LP variants in 31 genes, as well as 19 IRAs in APC and HOXB13.

A total of 129 patients with P/LP variants had staging data available. This information indicated that 70 patients had very high-risk disease (stage III/IV), 23 had high-risk disease (stage III), and 36 had intermediate- to low-risk disease (stage IIa, IIb, and IIc). Among patients who had P/LP variants or risk alleles, only 36% reported having a family history of prostate, breast, ovarian, or pancreatic cancer.

Our initial findings from this study of [patients with] prostate cancer found an overall positive rate of 16% with 75% of positive patients being eligible for implementation of gene-specific management guidelines, precision therapies and/or clinical treatment trials, the study authors wrote. Of patients with P/LP variants, 64% did not have a close family history of prostate, breast, ovarian, or pancreatic cancer, and therefore would not have been eligible for testing based on National Comprehensive Cancer Network (NCCN) criteria.

Current criteria for germline testing in patients who have been diagnosed with prostate cancer may present a barrier to some individuals, especially those who dont have specific features regarding personal or family history, according to the investigators. Previous data have suggested that these testing criteria can exclude patients who actually harbor germline variants, which could potentially lead to suboptimal care.2

To address this, investigators launched a sponsored testing program aimed at increasing access to germline genetic testing for patients with prostate cancer through the utilization of broader criteria and eliminating cost barriers.

The program launched in July 2019 and continued throughout October 2019. Each patient enrolled on the program underwent testing that included an 84-gene, multicancer germline panel. Positive results included P and LP variants as well as IRAs. Of the 986 patients enrolled, the majority, or 70% (n = 692), were Caucasian, 13% were African American (n = 127), 3% were Hispanic (n = 33), 1.7% were Ashkenazi Jewish (n = 17), 1.0% were Asian (n = 10), and the remaining 11% (n = 107) were of unreported, mixed, or other ethnicity.

Additional results showed that when investigators evaluated diagnostic yield by disease stage, the very high-risk subgroup had a positive rate of 16%, the high-risk subgroup had a positive rate of 17%, and the intermediate- to low-risk subgroup had a positive rate of 14%.

Overall, no association of statistical significance was observed between disease stage and germline positive rate. The intermediate-/low-risk patients, who would not be indicated for germline testing based on current guidelines, had a positive rate of 14% (including P/LP variants and IRAs), the study authors wrote. Of the 36 intermediate-/low-risk patients with positive variants, 27(75%) had variants in clinically actionable genes.

Notably, 71% of patients who tested positive had P/LP variants that confers eligibility for gene-specific targeted agents or clinical trials based on variants in homologous repair or mismatch repair genes, the authors added.

These data imply that broader testing criteria could help to better inform care for many patients who might otherwise be overlooked for testing, according to the authors. By reducing barriers to testing, the authors conclude that more patients with prostate cancer would have access to crucial actionable genetic information that could lead to more targeted treatment approaches that could potentially improve outcomes.

New Recommendations Call for Increased Access to Germline Testing

The 2019 Philadelphia Prostate Cancer Consensus Conference, which brought together healthcare experts, stakeholders, and leaders from national organizations, was held to address challenges with germline testing in clinical practice and to map out a framework to increase accessibility to testing in the precision medicine era.

To do this, the panel set 3 goals: to define optimal germline testing approaches that comprise expanded panel testing options and evolving genetic data, to determine consistent germline testing indications and management, and to establish alternative genetic evaluation models in order to compensate for the shortage of genetic counseling services.3

A total of 97 participants attended the conference; these included experts in urology, medical oncology, radiation oncology, clinical genetics, and genetic counseling spaces, among others. In total, 76 participants were included on the final voting panel.

Panel members conducted a literature review with thematic topics that focused on prostate cancer risk, germline mutations by clinical and molecular characteristics of the disease, clinical multigene testing data, germline mutations in diverse populations, genetic testing capabilities and considerations, genetic counseling implementation, NCCN genetic testing guidelines, genetic testing for precision medicine in the metastatic setting, germline implications for active surveillance of early-stage disease, and germline implications for early disease detection.

Large germline panels and somatic testing were recommended for metastatic prostate cancer. Reflex testing to examine priority genes followed by expanded testing was recommended for several scenarios. Investigators determined these priority genes to be BRCA1/2 and mismatch repair genes with regard to metastatic disease treatment, and ATM in broader testing to help determine clinical trial eligibility. Additionally, BRCA2 was suggested for active surveillance discussions.

Upon completion of their review, the panel established criteria for germline prostate cancer genetic testing. Men with metastatic disease, including those with castration-resistant or castration-sensitive prostate cancer, meet the criteria for testing. In order for patients with nonmetastatic disease to be considered for genetic testing, they must either be of Ashkenazi Jewish ancestry, have advanced disease, have intraductal or ductal pathology, or be grade group 4 (Gleason sum 8) or above. Patients who have a brother or father, or 2 or more male relatives, who received a prostate cancer diagnosis and were under 60 years of age, who died from prostate cancer, or who had metastatic disease should also be considered for testing.

For those with metastatic disease, priority germline testing was recommended for those with BRCA1/2, DNA MMR genes, and further gene testing based on family history. Somatic next-generation sequencing was recommended for all men with metastatic disease. Additionally, confirmatory germline testing for somatic mutations was recommended for those with BRCA2 genes.

Reflex testing may be optimal for patients with nonmetastatic disease, according to the panel. with a recommendation to test for BRCA2 variants. For patients without a prostate cancer diagnosis but with an applicable family history, priority genes for risk assessment include BRCA2 and HOXB13.

References:

More:
Increased Access to Germline Testing Needed in Prostate Cancer - OncLive

Cancer Genetics and StemoniX Sign Definitive Agreement to Merge – GlobeNewswire

Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions

RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the Company) (Nasdaq: CGIX), and StemoniX, Inc., today announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services. StemoniX, a privatecompany, isa leader in developing high-throughput disease-specifichuman organoid platforms integrated withleading-edge data science technologies. Under the terms of the merger agreement, StemoniX will merge with a newly formed subsidiary of Cancer Genetics in an all-equity transaction. Upon shareholder approval, the combined company expects to remain listed on the Nasdaq Stock Market. StemoniX will retain its name and become a wholly-owned subsidiary of Cancer Genetics.

The transaction will position the combined company to harness the synergies between two critical modalities of drug discovery and development - advanced animal models and relevant human high-throughput organoid platforms. The resulting integration of scientific and technology-based expertise, skilled management teams, and ability to offer customers an end-to-end platform will de-risk and accelerate development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. In combination, Cancer Genetics and StemoniX currently enjoy partnerships and R&D relationships with dozens of global pharmaceutical and biotechnology companies.

"The process of discovering and developing a new drug candidate takes years and comes with a price tag of hundreds of millions - or even billions - of dollars. However, we are at unique time in the drug discovery industry as the convergence of technological innovations in both biology and software will transform conventional workflows in time and accuracy. To convert the time-consuming and labor-intensive process of developing a drug for market, we now look to supplement traditional discovery and drug approval mechanisms to include humanized cell-based assays with artificial intelligence (AI) along with our core vivoPharm business. Given that our strategy and approach are strongly aligned with those of StemoniX, we are pleased to have moved forward with this proposed transaction," stated Jay Roberts, Chief Executive Officer of Cancer Genetics.

The pharma industry and society are at a critical pivot point. Viral pandemics and diseases lacking treatments require a new way of innovation. The proposed merger expects to expand our ability to engage with a larger audience of potential partners and expand our internal capabilities as we deliver on our mission to rapidly discover the safest and most effective therapeutics on behalf of our partners and our shareholders. The mission will stay consistent - allow scientists to quickly and economically conduct high-throughput toxicity and drug development studies in ready-to-assay plates containing functional microOrgans, stated Ping Yeh, Chief Executive Officer of StemoniX.

ABOUT THE TRANSACTION

Pursuant to the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock which will represent approximately 78% of the outstanding common stock of Cancer Genetics, subject to certain adjustments and prior to the effects of the financing referred to below, with the current equity holders of Cancer Genetics retaining 22% of the common stock immediately following the consummation of the merger.

The Boards of Directors of both companies have approved the proposed merger, which is expected to close in the fourth quarter of 2020, subject to the approval of the shareholders of both Cancer Genetics and StemoniX, financing and other customary closing conditions.

H.C. Wainwright & Co. is acting as financial advisors to the Board of Directors of Cancer Genetics, and Lowenstein Sandler is acting as its legal counsel. Northland Securities, Inc. is acting as financial advisor to the Board of Directors of StemoniX and Taft, Stettinius & Hollister is acting as its legal counsel.

ABOUT CANCER GENETICS

Through its vivoPharm subsidiary, Cancer Genetics offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. The Company is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit http://www.cancergenetics.com.

ABOUT STEMONIX, INC.

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. To learn more about how StemoniX products and services are accelerating discoveries, please visit http://www.StemoniX.com.

For more information, please visit or follow CGI at:

http://www.cancergenetics.com

Twitter: @Cancer_Genetics

And StemoniX at:

http://www.StemoniX.com

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.s expectations regarding satisfaction of closing conditions, consummation of the merger, future financial and/or operating results, and potential for our services, future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger, our attempts to adapt to the global coronavirus pandemic, achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs and conditions to the merger, properly evaluate strategic options, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Investor Contacts:Jennifer K. Zimmons. Ph.D.Investor RelationsZimmons International Communications, Inc.Email: jzimmons@zimmonsic.comPhone: +1.917.214.3514

Continue reading here:
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge - GlobeNewswire

Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP…

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSKs BLENREP (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics proprietary technology. BLENREP was developed and will be commercialized by GSK. In addition to the milestone payment, Seattle Genetics is entitled to royalties on BLENREP product sales. BLENREP was approved as monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

This is the second collaborator program utilizing our ADC technology to receive European Commission approval in 2020, and rapidly follows the FDA approval of BLENREP earlier this month, highlighting the potential of these novel therapies in the treatment of cancer patients globally, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Our ADC collaborator progress, along with the growth of Seattle Genetics marketed ADCs, ADCETRIS and PADCEV, and recent positive results of tisotumab vedotin from our ADC pipeline, underscore our leadership in ADCs to treat cancer.

BLENREP was granted PRIME (PRIority MEdicines) designation in 2017 and the application was reviewed under the European Medicines Agencys (EMA) accelerated assessment procedure, which is given if the Committee for Medicinal Products for Human Use of the EMA determines the treatment is of major interest from a public health perspective and represents a therapeutic innovation.

Seattle Genetics ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer. The technology has been licensed to several companies. Under the terms of these agreements, each licensee company has rights to use the technology with antibodies against specified targets. The licensee is responsible for research, product development, manufacturing and commercialization. Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on worldwide net sales of any resulting ADC products.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the Companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to anticipated milestone payments, fees, and royalties due to the company from GSK and other licensees, the therapeutic uses of BLENREP, the importance of ADCs in treating cancer and the companys leadership in the field of ADCs. Actual results or developments may differ materially from those projected or implied in these forward-looking statements due to factors such as unanticipated delays in or other obstacles to the development or commercialization of ADCs subject to these license agreements and the receipt by the Company of consideration from the subject ADC licenses. More information about the risks and uncertainties faced by the Company is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Visit link:
Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP...

Get Up to Speed on Hemp Genetics, Pollination, and More – Greenhouse Grower

The University of California, Davis Seed Biotechnology Center is hosting an online Hemp Breeding and Seed Production course from Oct. 27-29. The course is designed to enhance the knowledge of professionals working on hemp improvement and propagation.

Presentations will cover hemp seed production topics such as flowering, pollination, seed development, harvesting, and certification. Course participants also will learn about hemp genomics, genetics, sex expression, types of cultivars with corresponding breeding schemes, and intellectual property protection options. Instructors include experts from the public and private sectors and will be delivered online in an interactive format with lectures and discussions.

Click herefor more information and to register for the course.

Brian Sparks is senior editor of Greenhouse Grower and editor of Greenhouse Grower Technology. See all author stories here.

Follow this link:
Get Up to Speed on Hemp Genetics, Pollination, and More - Greenhouse Grower

Genetic Study Reveals Theres More to Melons Than Meets the Eye – Technology Networks

On the surface, the humble melon may just look like a tasty treat to most. But researchers from Japan have found that this fruit has hidden depths: retrotransposons (sometimes called "jumping sequences") may change how genes are expressed.

In a study published recently inCommunications Biology, researchers from the University of Tsukuba and the National Agriculture and Food Research Organization (NARO) have revealed that retrotransposons had a role in altering gene expression when melon genomes were diversifying, and may affect gene expression that induces fruit ripening.

Melons comprise one of the most economically important fruit crops globally. A special feature of melons is the coexistence of two fruit types: climacteric (which produce ethylene and exhibit a burst in cellular respiration as ripening begins), and non-climacteric. Ethylene is a plant hormone important to the regulation of climacteric fruit-ripening traits such as shelf life, which is of major economic importance.

"Because Harukei-3 melons produce ethylene during ripening, we wanted to look at ethylene-related gene expression in this type of melon," says lead author of the study Professor Hiroshi Ezura. "Harukei-3 produces an especially sweet fruit if grown in the right seasons. Because of its taste and attractive appearance, Harukei-3 has been used for a long time in Japan as a standard type for breeding high-grade muskmelon."

To examine ethylene-related gene expression, the researchers assembled the whole genome sequence of Harukei-3 by using third-generation nanopore sequencing paired with optical mapping and next-generation sequencing.

"We compared the genome of Harukei-3 with other melon genomes. Interestingly, we found that there are genome-wide presence/absence polymorphisms of retrotransposon-related sequences between melon accessions, and 160 (39%) were transcriptionally induced in post-harvest ripening fruit samples. They were also co-expressed with neighboring genes," explains Dr. Ryoichi Yano, senior author. "We also found that some retrotransposon-related sequences were transcribed when the plants were subjected to heat stress."

Retrotransposons are transposons (also referred to as "jumping sequences" because they can change their positions within a genome) with sequences similar to those of retroviruses.

"Our findings suggest that retrotransposons contributed to changes in gene expression patterns when melon genomes were diversifying. Retrotransposons may also affect gene expression that brings on fruit ripening," says Professor Ezura.

The Harukei-3 genome assembly, together with other data generated in this study, is available in the Melonet-DB database. Combined with future updates, this database will contribute to the functional genomic study of melons, especially reverse genetics using genome editing.

Reference: Yano et al. (2020).Comparative genomics of muskmelon reveals a potential role for retrotransposons in the modification of gene expression. Communications Biology.DOI: https://doi.org/10.1038/s42003-020-01172-0.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
Genetic Study Reveals Theres More to Melons Than Meets the Eye - Technology Networks

Landmark piglets ready to hog the spotlight – The Pig Site

After years of extensive collaborative efforts from many organisations, new life and new genetics are being introduced to American Large Black Hog herds thanks to 25 half-British Large Black piglets born at Purdue University.

Solid black, deep-bodied swine with lop ears that cover their eyes, Large Blacks have long been prized for their docile nature, superior mothering abilities and succulent pork. Despite these qualities, the Large Black Hog is in global danger of extinction. Fewer than 150 purebred animals were registered in the United States in 2019. Through partnerships with breeders, universities, private donors, USDA, industry leaders and food organisations, The Livestock Conservancy is working to save this unique breed for future farming generations.

Small populations, like the Large Black, can quickly lose genetic diversity and suffer from inbreeding depression. This can lead to declines in fitness traits, including reproductive ability. To infuse new genetics into this US heritage swine population, The Livestock Conservancy imported frozen semen from two Large Black boars from the UK in 2015. Importation was made possible by a significant gift from an anonymous donor, several additional private donations, as well as partnerships with the USDAs National Animal Germplasm Program (NAGP), Large Black Hog Association, Gloucestershire Old Spots America, British Pig Association, and Deerpark Pedigree Pigs of the UK.

The Livestock Conservancy and NAGP subsequently conducted inseminations during several on-farm trials. Despite efforts of the best swine reproduction specialists in the US and participating farmers who have worked with this breed for decades, none of these attempts produced live piglets. The experts soon realised heritage breed pig reproductive cycling is different from commercial pigs, where artificial insemination is common.

Dr Kara Stewart, assistant professor of Animal Sciences at Purdue University with a specialty in reproductive physiology, and graduate student Katharine Sharp, began exploring methods to control and synchronise ovulation of Large Black sows to identify ideal times for insemination. Thawed semen is only viable for a short time period, so predictable timing of ovulation and insemination is critical to the successful use of frozen semen. Twenty Large Black female pigs were donated to The Livestock Conservancy from breeders across the nation and were transported from their home farms to Purdue University in 2018 to launch this research.

"When I heard that The Livestock Conservancy was having trouble finding enough girls for this research project, I thought I would donate four sisters that were weaned and ready to go," said Felicia Krock, registrar and secretary of the Large Black Hog Association and a member of The Livestock Conservancy. "I thought if there were issues with the bloodline it would raise its ugly head through the use of three of my girls who were full siblings and one who was a half sibling to them. This was such a great opportunity to enhance the survivability of a very special breed."

For nearly two years, Purdue scientists studied female reproduction for the breed, first using less expensive frozen semen from US pigs to test their insemination protocols. The researchers refined a Large Black sow cycling protocol that allowed them to predict ovulation, thaw semen at just the right time, and inseminate the females. Each insemination trial at Purdue saw greater improvements in the rate of conception and number of live births. Pigs produced from these trials were used in further research projects to document growth and meat characteristics for the endangered breed.

The next, and most expensive, step was using the frozen, imported semen to create half-British and half-American piglets. The hard work paid off. Half-British piglets were born in May 2020 from five sows. The little boars and gilts are being distributed across the US to broaden the genetic base for the Large Black breed.

Preservation of heritage breeds is important to help maintain the genetic diversity of our livestock, said David Burgett, a member of both The Livestock Conservancy and the Large Black Hog Association, who recently received a few of the piglets at his Illinois farm. Having dwindled to such a small population, the Large Black Hog, through years of inbreeding with the limited number of bloodlines available in the United States, was in danger of losing some of the diverse traits inherent to specific blood lines. With the importation of British bloodlines comes the responsibility to work together as members of the Large Black Hog Association to improve the herd, to promote the breed and the characteristics that make it unique and so desirable, and build the population back up to avoid its extinction. We are grateful that we had this chance to participate in the joint project with The Livestock Conservancy and Purdue University to improve the future, and promote the survival of the Large Black Hog.

A second breeding with imported semen will be conducted this fall to produce more piglets. Researchers plan to share their research results and techniques with farmers, enabling them to do on-farm artificial insemination and produce their own Large Black breeding stock. These new techniques for using frozen semen on heritage breed pigs will allow Large Black boar semen to be more widely exchanged among the nations breeders to keep their herds genetically healthy. The new frozen semen protocols may be useful for other heritage pig breeds, as well.

The Livestock Conservancys Swine Initiative with Large Black pigs illustrates the power of collaboration and technology to advance rare breed conservation.

Click here to learn more about Large Black pigs.

Read more:
Landmark piglets ready to hog the spotlight - The Pig Site

In Brief This Week: Myriad Genetics, Illumina, Quest, and More – 360Dx

NEW YORK Fujifilm Medical Systems said this week that it will integrate Fujifilm Wako Diagnostics into its business, effective Oct. 1. As a result, Fujifilm Wakos portfolio of in vitro diagnostic products will be added to Fujifilm Medicals product offerings. Wako Diagnostics was originally acquired by Fujifilm in 2017 and has been operating as a separate subsidiary.

View original post here:
In Brief This Week: Myriad Genetics, Illumina, Quest, and More - 360Dx